Vibegron
Brand names: Obgemsa
Vibegron is an oral beta-3 adrenergic receptor agonist used for the symptomatic treatment of overactive bladder, including urgency, urgency incontinence and frequency.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively stimulates beta-3 adrenoceptors in the detrusor muscle, promoting bladder smooth muscle relaxation during the storage phase to increase bladder capacity.
Prescribing in practice
- Avoid in patients with severe uncontrolled hypertension and monitor blood pressure, as beta-3 agonists can raise it.
- It offers an alternative to antimuscarinics, which may be useful where anticholinergic burden is a concern.
- Review response after an adequate treatment period and reassess if symptoms do not improve.
Monitoring
Monitor blood pressure before and periodically during treatment, particularly in patients with pre-existing hypertension.
Counselling the patient
- It helps reduce the sudden urge to pass urine and may take some weeks to reach full effect.
- Report any difficulty passing urine or new high blood pressure symptoms.
- Swallow tablets whole and take regularly as prescribed.
Evidence & guidelines
Use is supported by randomised controlled trials demonstrating reduced micturition frequency and urgency incontinence episodes in overactive bladder.
Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.